Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 4:51 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 625–648 of 9,813 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Cancer, Advanced Clear all

Conditions: Unspecified Adult Solid Tumor, Protocol Specific
Interventions: bizelesin; Drug
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2002
U.S. locations: 2
States / cities: Fort Sam Houston, Texas • San Antonio, Texas

Conditions: Head and Neck Cancer
Interventions: Cetuximab, Radiation Therapy; Drug · Radiation
Lead sponsor: University of Cincinnati; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2022
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: RAS Mutation, NRAS Gene Mutation, Melanoma
Interventions: OKI-179 + binimetinib; Drug
Lead sponsor: OnKure, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 12
States / cities: Phoenix, Arizona • San Francisco, California • Gainesville, Florida + 9 more

Conditions: Breast Cancer
Interventions: Capecitabine; Drug
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older · Female only
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2013
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Metastatic Solid Tumors, Esophageal Cancer, Non-Small Cell Lung Cancer
Interventions: M1231; Drug
Lead sponsor: EMD Serono Research & Development Institute, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 2
States / cities: Houston, Texas • San Antonio, Texas

Conditions: Solid Cancers
Interventions: GDC-0941; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2013
U.S. locations: 3
States / cities: Scottsdale, Arizona • Boston, Massachusetts • Detroit, Michigan

Conditions: Urothelial Cancer
Interventions: Erdafitinib, Vinflunine, Docetaxel, Pembrolizumab, Fibroblast Growth Factor Receptor inhibitor Clinical Trial Assay (FGFRi CTA); Drug · Device
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 629 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 26
States / cities: Anchorage, Alaska • Sacramento, California • St. Helena, California + 22 more

Conditions: Non Small Cell Lung Cancer
Interventions: Calcitriol; Drug
Lead sponsor: University of Michigan Rogel Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 4
States / cities: Ann Arbor, Michigan • Buffalo, New York

Conditions: Adenocarcinoma of the Gastroesophageal Junction, Adenocarcinoma of the Stomach, Recurrent Gastric Cancer, Stage IIIA Gastric Cancer, Stage IIIB Gastric Cancer, Stage IIIC Gastric Cancer, Stage IV Gastric Cancer
Interventions: oxaliplatin, leucovorin calcium, fluorouracil, placebo, vismodegib, laboratory biomarker analysis; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 30
States / cities: Sacramento, California • Chicago, Illinois • Decatur, Illinois + 16 more

Conditions: Gastrointestinal Stromal Tumors, Advanced Systemic Mastocytosis, Advanced Cancers
Interventions: DCC-2618; Drug
Lead sponsor: Deciphera Pharmaceuticals, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 282 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2022
U.S. locations: 16
States / cities: Scottsdale, Arizona • Los Angeles, California • Palo Alto, California + 10 more

Conditions: Advanced Hematological Disorders
Interventions: ORH-2014; Drug
Lead sponsor: Orsenix LLC; Industry
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 4
States / cities: New York, New York • Nashville, Tennessee • Houston, Texas

Conditions: Advanced Cancer, Pain
Interventions: I-STAMP; Behavioral
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 21 Years and older
Enrollment: 73 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Nonsmall Cell Lung Cancer, Stage II, Nonsmall Cell Lung Cancer Stage III
Interventions: Hypofractionated Radiation Therapy, Radiation Boost; Drug · Radiation
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Melanoma (Skin)
Interventions: hu14.18-IL2 fusion protein; Biological
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2014
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Colorectal Cancer, Diarrhea
Interventions: celecoxib, irinotecan hydrochloride; Drug
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2005
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Locally Advanced Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Solid Tumor, Urothelial Carcinoma, Solid Tumor, Adult, Bladder Cancer, Non-muscle-invasive Bladder Cancer, FGFR3 Gene Mutation, FGFR3 Gene Alteration, Advanced Solid Tumor, Advanced Urothelial Carcinoma, Urinary Tract Cancer, Urinary Tract Tumor, Urinary Tract Carcinoma
Interventions: TYRA-300; Drug
Lead sponsor: Tyra Biosciences, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 310 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 7
States / cities: Boston, Massachusetts • Worchester, Massachusetts • New York, New York + 4 more

Conditions: Advanced Solid Tumors, Metastatic Solid Tumors, Non-small Cell Lung Cancer (NSCLC), NSCLC, Colorectal Cancer (CRC), CRC
Interventions: Daraxonrasib, Elironrasib, Zoldonrasib, Ivonescimab, Carboplatin/Cisplatin + Pemetrexed (Dose Expansion Only), cetuximab (Cohort C2 Only), Carboplatin/Cisplatin + Pemetrexed (Cohort B2 Only), Daraxonrasib (Cohort B1 only); Drug
Lead sponsor: Revolution Medicines, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 370 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 19
States / cities: Scottsdale, Arizona • Los Angeles, California • San Francisco, California + 15 more

Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: Spartalizumab, Capmatinib, spartalizumab placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Breast Cancer
Interventions: Carboplatin, Everolimus; Drug
Lead sponsor: Amy Tiersten; Other
Eligibility: 18 Years and older · Female only
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2024
U.S. locations: 3
States / cities: New York, New York

Conditions: Breast Cancer
Interventions: Taselisib, Placebo, Fulvestrant; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 631 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 16
States / cities: Tucson, Arizona • Atlanta, Georgia • Marietta, Georgia + 12 more

Conditions: High Grade Serous Adenocarcinoma of Ovary, Fallopian Tube Cancer, Primary Peritoneal Carcinoma, Chromosomal Instability
Interventions: Sovilnesib; Drug
Lead sponsor: Volastra Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 11
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Newport Beach, California + 8 more

Conditions: Gastroenteropancreatic Neuroendocrine Tumors
Interventions: Not listed
Lead sponsor: Ipsen; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 12
States / cities: Sedona, Arizona • Denver, Colorado • Arlington Heights, Illinois + 8 more

Conditions: Cancer
Interventions: AZD2281, AZD5363, AZD1775, AZD6738; Drug
Lead sponsor: Joseph Paul Eder; Other
Eligibility: 18 Years and older
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 4
States / cities: New Haven, Connecticut • Boston, Massachusetts • Cleveland, Ohio + 1 more

Conditions: Melanoma
Interventions: LGX818; Drug
Lead sponsor: Array BioPharma; Industry
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Nashville, Tennessee

Search by objective public record fields.

Bizelesin in Treating Patients With Advanced Cancer

Post-operative Radiation With Cetuximab for Locally Advanced Cutaneous Squamous Cell Carcinoma of the Head and Neck

NAUTILUS: OKI-179 Plus Binimetinib in Patients with Advanced Solid Tumors in the RAS Pathway (Phase 1b) and NRAS-mutated Melanoma (Phase 2)

Capecitabine as NeoAdjuvant Therapy in Locally Advanced Breast Cancer

M1231 in Participants With Solid Tumors

A Study of GDC-0941 in Participants With Locally Advanced or Metastatic Solid Tumors for Which Standard Therapy Either Does Not Exist or Has Proven Ineffective or Intolerable

A Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Participants With Advanced Urothelial Cancer and Selected Fibroblast Growth Factor Receptor (FGFR) Gene Aberrations

Phase I/II Calcitriol in Lung Cancer

Combination Chemotherapy With or Without Vismodegib in Treating Patients With Advanced Stomach Cancer or Gastroesophageal Junction Cancer

A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies

A Phase I, Two-part Study to Determine the Recommended Dose and Evaluate the Safety and Tolerability of a Novel Oral Arsenic Trioxide Formulation (ORH-2014) in Subjects With Advanced Hematological Disorders

Integrated Smartphone Technology to Alleviate Malignant Pain (I-STAMP) Testing

Study of Hypofractionated Radiotherapy Alone in Locally Advanced Nonsmall Cell Lung Cancer Patients

Hu14.18-Interleukin-2 Fusion Protein in Treating Patients With Advanced Melanoma

Irinotecan and Celecoxib in Treating Patients With Unresectable or Metastatic Colorectal Cancer

Safety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors With FGFR3 Gene Alterations

Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors

Study of Capmatinib and Spartalizumab/Placebo in Advanced NSCLC Patients With MET Exon 14 Skipping Mutations

Comparison of Single-Agent Carboplatin vs the Combination of Carboplatin and Everolimus for the Treatment of Advanced Triple-Negative Breast Cancer

A Study of Taselisib + Fulvestrant Versus Placebo + Fulvestrant in Participants With Advanced or Metastatic Breast Cancer Who Have Disease Recurrence or Progression During or After Aromatase Inhibitor Therapy

A Study of Sovilnesib in Subjects With Ovarian Cancer

Community-based Neuroendocrine Tumor (NET) Research Study

OLAParib COmbinations

LGX818 in Combination With Agents (MEK162; BKM120; LEE011; BGJ398; INC280) in Advanced BRAF Melanoma